Repligen Company Profile (NASDAQ:RGEN)

About Repligen (NASDAQ:RGEN)

Repligen logoRepligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company's portfolio includes protein products, chromatography products, and filtration products. It provides Protein A ligands, a component of Protein A chromatography resins (media) used in the purification of virtually all monoclonal antibody (mAb)-based drugs on the market or in development. Its chromatography portfolio includes various products used in the downstream purification and quality control of biological drugs. Its OPUS pre-packed chromatography columns (PPCs) are used in the purification of clinical-stage biologics. Its filtration products include XCell Alternating Tangential Flow (ATF) Systems and Sius tangential flow filtration (TFF) cassettes. Sius TFF cassettes are used to concentrate clinical and commercial-stage biologic drugs.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:RGEN
  • CUSIP: 75991610
  • Web: www.repligen.com
Capitalization:
  • Market Cap: $1.34 billion
  • Outstanding Shares: 34,080,000
Average Prices:
  • 50 Day Moving Avg: $36.98
  • 200 Day Moving Avg: $33.19
  • 52 Week Range: $21.11 - $39.96
P/E:
  • Trailing P/E Ratio: 103.59
  • Foreward P/E Ratio: 54.53
  • P/E Growth: 2.78
Sales & Book Value:
  • Annual Revenue: $110.04 million
  • Price / Sales: 12.16
  • Book Value: $5.19 per share
  • Price / Book: 7.56
Profitability:
  • EBIDTA: $27.41 million
  • Net Margins: 6.89%
  • Return on Equity: 10.16%
  • Return on Assets: 6.87%
Debt:
  • Debt-to-Equity Ratio: 0.57%
  • Current Ratio: 10.89%
  • Quick Ratio: 9.68%
Misc:
  • Average Volume: 254,825 shs.
  • Beta: 1.58
  • Short Ratio: 15.43
 

Frequently Asked Questions for Repligen (NASDAQ:RGEN)

What is Repligen's stock symbol?

Repligen trades on the NASDAQ under the ticker symbol "RGEN."

How were Repligen's earnings last quarter?

Repligen Co. (NASDAQ:RGEN) released its earnings results on Thursday, May, 4th. The company reported $0.15 EPS for the quarter, topping the Zacks' consensus estimate of $0.13 by $0.02. The firm earned $30.59 million during the quarter, compared to the consensus estimate of $29.28 million. Repligen had a return on equity of 10.16% and a net margin of 6.89%. The company's revenue was up 21.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.12 earnings per share. View Repligen's Earnings History.

When will Repligen make its next earnings announcement?

Repligen is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for Repligen.

Where is Repligen's stock going? Where will Repligen's stock price be in 2017?

3 analysts have issued 1 year price objectives for Repligen's shares. Their forecasts range from $30.00 to $40.00. On average, they anticipate Repligen's share price to reach $35.67 in the next twelve months. View Analyst Ratings for Repligen.

Who are some of Repligen's key competitors?

Who owns Repligen stock?

Repligen's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (13.78%), TimesSquare Capital Management LLC (5.82%), OppenheimerFunds Inc. (5.69%), Vanguard Group Inc. (5.35%), FMR LLC (3.71%) and Conestoga Capital Advisors LLC (3.59%). Company insiders that own Repligen stock include Anthony Hunt, Howard Benjamin, Jon Snodgres, Karen A Dawes and Thomas F Ryan Jr. View Institutional Ownership Trends for Repligen.

Who sold Repligen stock? Who is selling Repligen stock?

Repligen's stock was sold by a variety of institutional investors in the last quarter, including Kalmar Investments Inc. DE, Renaissance Technologies LLC, Bank of New York Mellon Corp, Oxford Asset Management, Alliancebernstein L.P., Russell Investments Group Ltd., Schwab Charles Investment Management Inc. and FMR LLC. Company insiders that have sold Repligen stock in the last year include Anthony Hunt, Howard Benjamin, Jon Snodgres, Karen A Dawes and Thomas F Ryan Jr. View Insider Buying and Selling for Repligen.

Who bought Repligen stock? Who is buying Repligen stock?

Repligen's stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., TimesSquare Capital Management LLC, MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., Cortina Asset Management LLC, Vanguard Group Inc., Conestoga Capital Advisors LLC and Schroder Investment Management Group. View Insider Buying and Selling for Repligen.

How do I buy Repligen stock?

Shares of Repligen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Repligen stock cost?

One share of Repligen stock can currently be purchased for approximately $39.26.

Analyst Ratings

Consensus Ratings for Repligen (NASDAQ:RGEN) (?)
Ratings Breakdown: 2 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $35.67 (9.15% downside)

Analysts' Ratings History for Repligen (NASDAQ:RGEN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/21/2017First AnalysisReiterated RatingEqual Weight$40.00LowView Rating Details
12/21/2016Jefferies Group LLCReiterated RatingHold$28.00 -> $30.00N/AView Rating Details
12/18/2016StephensSet Price TargetBuy$37.00N/AView Rating Details
2/22/2016Craig HallumInitiated CoverageBuyN/AView Rating Details
(Data available from 5/28/2015 forward)

Earnings

Earnings History for Repligen (NASDAQ:RGEN)
Earnings by Quarter for Repligen (NASDAQ:RGEN)
Earnings History by Quarter for Repligen (NASDAQ:RGEN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2017        
5/4/20173/31/2017$0.13$0.15$29.28 million$30.59 millionViewListenView Earnings Details
2/22/2017Q416$0.07$0.08$24.05 million$25.60 millionViewListenView Earnings Details
11/3/2016Q316$0.08$0.08$24.39 million$24.70 millionViewN/AView Earnings Details
8/4/2016Q216$0.13$0.16$24.75 million$29.20 millionViewN/AView Earnings Details
5/5/2016Q116$0.10$0.12$22.54 million$25.10 millionViewN/AView Earnings Details
2/25/2016Q415$0.07$0.07$19.84 million$21.40 millionViewListenView Earnings Details
11/5/2015Q315$0.08$0.08$20.50 million$19.80 millionViewN/AView Earnings Details
8/6/2015Q215$0.08$0.11$20.05 million$21.50 millionViewN/AView Earnings Details
5/7/2015Q115$0.07$0.09$18.20 million$20.82 millionViewN/AView Earnings Details
3/13/2015Q414$0.04($0.01)$14.70 million$15.40 millionViewN/AView Earnings Details
11/6/2014Q314$0.04$0.04$15.60 million$15.30 millionViewN/AView Earnings Details
8/11/2014Q114$0.06$0.09$14.90 million$15.60 millionViewN/AView Earnings Details
5/8/2014Q1$0.07$0.13$15.14 million$16.33 millionViewListenView Earnings Details
3/6/2014Q413$0.14$0.10$15.88 million$10.40 millionViewListenView Earnings Details
11/7/2013Q313$0.13$0.18$16.27 million$18.80 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.10$0.14$15.97 million$17.50 millionViewListenView Earnings Details
5/2/2013Q1 2013$0.07$12.82 million$16.46 millionViewListenView Earnings Details
11/8/2012Q312$0.06$8.63 million$15.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Repligen (NASDAQ:RGEN)
2017 EPS Consensus Estimate: $0.54
2018 EPS Consensus Estimate: $0.67
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.13$0.13$0.13
Q2 20173$0.15$0.17$0.16
Q3 20172$0.13$0.13$0.13
Q4 20173$0.12$0.13$0.13
Q1 20182$0.16$0.17$0.17
Q2 20181$0.17$0.17$0.17
Q3 20181$0.16$0.16$0.16
Q4 20181$0.17$0.17$0.17
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Repligen (NASDAQ:RGEN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Repligen (NASDAQ:RGEN)
Insider Ownership Percentage: 2.30%
Institutional Ownership Percentage: 94.35%
Insider Trades by Quarter for Repligen (NASDAQ:RGEN)
Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)
Insider Trades by Quarter for Repligen (NASDAQ:RGEN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/21/2017Karen A DawesDirectorSell2,521$34.12$86,016.52View SEC Filing  
3/20/2017Howard BenjaminVPSell12,216$34.62$422,917.92View SEC Filing  
3/20/2017Thomas F Ryan JrDirectorSell4,000$34.83$139,320.00View SEC Filing  
3/17/2017Jon SnodgresCFOSell1,909$34.91$66,643.19View SEC Filing  
11/28/2016Anthony HuntCEOSell5,000$33.12$165,600.00View SEC Filing  
9/14/2016Thomas F Ryan JrDirectorSell2,700$32.58$87,966.00View SEC Filing  
6/30/2016Thomas F Ryan JrDirectorSell5,000$26.60$133,000.00View SEC Filing  
6/28/2016Thomas F Ryan JrDirectorSell10,000$24.59$245,900.00View SEC Filing  
5/11/2016Howard BenjaminVPSell2,889$26.72$77,194.08View SEC Filing  
6/9/2015Howard BenjaminVPSell35,000$38.14$1,334,900.00View SEC Filing  
5/11/2015Walter C HerlihyCEOSell104,569$37.94$3,967,347.86View SEC Filing  
5/8/2015Thomas F Ryan JrDirectorSell20,000$37.19$743,800.00View SEC Filing  
3/23/2015Walter C HerlihyCEOSell24,536$31.78$779,754.08View SEC Filing  
3/19/2015James R RuscheSVPSell14,650$33.30$487,845.00View SEC Filing  
3/19/2015Thomas F Ryan JrDirectorSell10,000$32.62$326,200.00View SEC Filing  
3/19/2015Walter C HerlihyCEOSell49,695$33.08$1,643,910.60View SEC Filing  
3/18/2015Howard BenjaminVPSell15,795$32.63$515,390.85View SEC Filing  
11/19/2014Walter C HerlihyCEOSell51,386$23.43$1,203,973.98View SEC Filing  
11/13/2014Thomas F Ryan JrDirectorSell10,000$23.81$238,100.00View SEC Filing  
11/11/2014Howard BenjaminVPSell30,000$23.56$706,800.00View SEC Filing  
11/10/2014Michael A GriffithDirectorSell23,342$22.90$534,531.80View SEC Filing  
8/13/2014Howard BenjaminVPSell40,000$20.34$813,600.00View SEC Filing  
6/27/2014Thomas F Ryan JrDirectorSell10,000$22.41$224,100.00View SEC Filing  
6/24/2014Thomas F Ryan JrDirectorSell10,000$21.78$217,800.00View SEC Filing  
6/11/2014Walter C HerlihyCEOSell60,335$20.11$1,213,336.85View SEC Filing  
6/9/2014James R RuscheSVPSell30,000$20.19$605,700.00View SEC Filing  
6/6/2014Daniel P WittSVPSell47,709$20.56$980,897.04View SEC Filing  
4/15/2014Daniel P WittSVPBuy10,000$3.05$30,500.00View SEC Filing  
8/8/2013James R RuscheSVPSell30,000$10.01$300,300.00View SEC Filing  
6/21/2013Karen A DawesDirectorBuy1,000$7.70$7,700.00View SEC Filing  
5/17/2013Thomas F Ryan JrDirectorSell21,000$8.97$188,370.00View SEC Filing  
5/15/2013Thomas F Ryan JrDirectorSell86,039$9.01$775,211.39View SEC Filing  
5/15/2013Walter C HerlihyCEOSell40,000$8.97$358,800.00View SEC Filing  
9/21/2012Glenn L Md CooperDirectorBuy10,000$6.09$60,900.00View SEC Filing  
8/16/2012Michael A GriffithDirectorBuy2,000$4.88$9,760.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Repligen (NASDAQ:RGEN)
Latest Headlines for Repligen (NASDAQ:RGEN)
Source:
DateHeadline
finance.yahoo.com logoRepligen to Participate in 14th Annual Craig-Hallum Institutional Investor Conference
finance.yahoo.com - May 24 at 9:46 AM
americanbankingnews.com logoFirst Analysis Analysts Cut Earnings Estimates for Repligen Co. (RGEN)
www.americanbankingnews.com - May 24 at 7:30 AM
americanbankingnews.com logoZacks: Repligen Co. (RGEN) Given $38.00 Consensus Price Target by Analysts
www.americanbankingnews.com - May 16 at 6:42 PM
americanbankingnews.com logo$31.47 Million in Sales Expected for Repligen Co. (RGEN) This Quarter
www.americanbankingnews.com - May 12 at 3:44 PM
americanbankingnews.com logoRepligen Co. (RGEN) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - May 11 at 9:44 AM
americanbankingnews.com logoRepligen Co. (RGEN) Expected to Post Earnings of $0.16 Per Share
www.americanbankingnews.com - May 10 at 7:42 AM
feeds.benzinga.com logoRepligen to Present at Bank of America Merrill Lynch 2017 Healthcare Conference
feeds.benzinga.com - May 9 at 2:48 PM
americanbankingnews.com logoEquities Analysts Issue Forecasts for Repligen Co.'s Q2 2017 Earnings (RGEN)
www.americanbankingnews.com - May 8 at 8:21 AM
americanbankingnews.com logoQ3 2017 EPS Estimates for Repligen Co. (RGEN) Boosted by Jefferies Group
www.americanbankingnews.com - May 5 at 10:56 AM
investorplace.com logoTrade of the Day: Repligen (NASDAQ:RGEN)
investorplace.com - May 5 at 8:26 AM
finance.yahoo.com logoEdited Transcript of RGEN earnings conference call or presentation 4-May-17 12:30pm GMT
finance.yahoo.com - May 5 at 12:45 AM
americanbankingnews.com logoRepligen Co. (RGEN) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS
www.americanbankingnews.com - May 4 at 10:26 PM
finance.yahoo.com logoInvestor Network: Repligen Corporation to Host Earnings Call
finance.yahoo.com - May 4 at 7:45 PM
finance.yahoo.com logoRepligen Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 4 at 7:45 PM
marketbeat.com logoRepligen tops Street 1Q forecasts
marketbeat.com - May 4 at 7:54 AM
americanbankingnews.com logoRepligen (RGEN) Receiving Somewhat Favorable Press Coverage, AlphaOne Reports
www.americanbankingnews.com - May 3 at 1:03 AM
finance.yahoo.com logoETFs with exposure to Repligen Corp. : May 1, 2017
finance.yahoo.com - May 1 at 6:48 PM
americanbankingnews.com logoFavorable News Coverage Extremely Likely to Impact Repligen (RGEN) Share Price
www.americanbankingnews.com - April 27 at 4:24 PM
americanbankingnews.com logoSomewhat Positive Press Coverage Somewhat Unlikely to Impact Repligen (RGEN) Share Price
www.americanbankingnews.com - April 23 at 5:51 PM
americanbankingnews.com logoRepligen Co. (RGEN) Now Covered by First Analysis
www.americanbankingnews.com - April 21 at 10:16 PM
finance.yahoo.com logoETFs with exposure to Repligen Corp. : April 21, 2017
finance.yahoo.com - April 21 at 7:18 PM
finance.yahoo.com logoRepligen to Report First Quarter 2017 Financial Results
finance.yahoo.com - April 21 at 8:33 AM
americanbankingnews.com logoRepligen (RGEN) Earning Somewhat Negative Media Coverage, Study Finds
www.americanbankingnews.com - April 20 at 8:35 PM
americanbankingnews.com logoRepligen Co. (RGEN) Expected to Announce Earnings of $0.13 Per Share
www.americanbankingnews.com - April 19 at 10:39 AM
americanbankingnews.com logoZacks: Repligen Co. (RGEN) Given $35.33 Consensus Price Target by Brokerages
www.americanbankingnews.com - April 17 at 11:31 AM
americanbankingnews.com logoRepligen (RGEN) Getting Somewhat Negative Media Coverage, Analysis Finds
www.americanbankingnews.com - April 14 at 3:32 PM
americanbankingnews.com logoRepligen Co. (RGEN) Short Interest Update
www.americanbankingnews.com - April 14 at 3:16 PM
finance.yahoo.com logoETFs with exposure to Repligen Corp. : April 7, 2017
finance.yahoo.com - April 7 at 7:54 PM
americanbankingnews.com logo Brokerages Set $35.33 Target Price for Repligen Co. (RGEN)
www.americanbankingnews.com - March 31 at 2:08 PM
americanbankingnews.com logoInsider Selling: Repligen Co. (RGEN) Director Sells 2,521 Shares of Stock
www.americanbankingnews.com - March 22 at 8:06 PM
americanbankingnews.com logoInsider Selling: Repligen Co. (RGEN) Director Sells 4,000 Shares of Stock
www.americanbankingnews.com - March 22 at 8:04 PM
americanbankingnews.com logoRepligen Co. (RGEN) VP Sells $422,917.92 in Stock
www.americanbankingnews.com - March 22 at 7:44 PM
americanbankingnews.com logoRepligen Co. (RGEN) CFO Sells $66,643.19 in Stock
www.americanbankingnews.com - March 21 at 10:16 PM
finance.yahoo.com logoREPLIGEN CORP Financials
finance.yahoo.com - March 1 at 7:45 PM
biz.yahoo.com logoREPLIGEN CORP Files SEC form 8-K/A, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhi
biz.yahoo.com - March 1 at 7:45 PM
investopedia.com logoTop 3 Healthcare Penny Stocks for 2017
www.investopedia.com - March 1 at 12:06 PM
finance.yahoo.com logoEdited Transcript of RGEN earnings conference call or presentation 22-Feb-17 1:30pm GMT
finance.yahoo.com - February 23 at 12:43 AM
seekingalpha.com logoRepligen's (RGEN) CEO Tony Hunt on Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - February 22 at 7:41 PM
us.rd.yahoo.com logoRepligen Reports Fourth Quarter 2016 Financial Results, Provides Guidance for 2017
us.rd.yahoo.com - February 22 at 9:34 AM
us.rd.yahoo.com logo7:32 am Repligen beats by $0.01, beats on revs; guides FY17 EPS in-line, revs in-line
us.rd.yahoo.com - February 22 at 9:34 AM
biz.yahoo.com logoREPLIGEN CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
us.rd.yahoo.com - February 22 at 9:34 AM
finance.yahoo.com logoRepligen To Report Fourth Quarter and Full Year 2016 Financial Results, Provides Financial Guidance for 2017
finance.yahoo.com - February 16 at 7:09 PM
finance.yahoo.com logoRepligen upgraded by Piper Jaffray
finance.yahoo.com - February 14 at 5:37 AM
finance.yahoo.com logoThe Zacks Analyst Blog Highlights: Sucampo Pharmaceuticals, Dr. Reddy's Laboratories, BioMarin Pharmaceutical and Repligen
finance.yahoo.com - February 7 at 12:39 AM
seekingalpha.com logoRepligen Corporation (RGEN) Presents At 35th Annual J.P. Morgan Healthcare Conference
seekingalpha.com - January 14 at 5:41 AM
globenewswire.com logoRepligen to Present at 35th Annual J.P. Morgan Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - January 5 at 1:17 AM
us.rd.yahoo.com logoRepligen to Present at 35th Annual J.P. Morgan Healthcare Conference
us.rd.yahoo.com - January 4 at 8:16 PM
finance.yahoo.com logo6:58 am Repligen acquires TangenX Technology for $39 mln in cash; RGEN expects earnings accretion in 2017
finance.yahoo.com - December 16 at 12:34 AM
finance.yahoo.com logoRepligen Acquires TangenX Technology Corporation
finance.yahoo.com - December 16 at 12:34 AM
finance.yahoo.com logoUPDATE -- Repligen Acquires TangenX Technology Corporation
finance.yahoo.com - December 16 at 12:34 AM

Social

Chart

Repligen (RGEN) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by MarketBeat.com Staff